Vernon W Anthony's Form 4 filing
NovoCure Ltd (NVCR) · filed Jun 6, 2024
- Accession no.
- 0001562180-24-004761
- Filed
- Jun 6, 2024
- Trade date
- Jun 4-5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $23.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vernon W AnthonyCIK 0001369091 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2024 | Ordinary Shares | SSaleDisposed | −964 | $23.89F1 | −$23,029.96 | 164,833 | Direct | |
| Jun 5, 2024 | Restricted Stock Units | AGrant or awardAcquired | +4,053 | $0.00 | $0 | 169,850 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 | Ordinary Shares | AGrant or awardAcquired | +6,229 | $0.00 | $0 | 6,229 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices ranging from $23.78 USD to $24.00 USD; the price reported above reflects the weighted average sale price.
Referenced by the price of 1 transaction in Table I.